Class I
The GREAT score predicts the likelihood of remission from Graves\' disease after a standard course (12–18 months) of anti-thyroid drugs.
Verified
Last Review: 2026
| Factor | Score 0 | Score 1 | Score 2 |
|---|---|---|---|
| Age | ≥ 40 yrs | - | < 40 yrs |
| FT4 (pmol/L) | < 40 | 40 – 60 | > 60 |
| TRAb (IU/L) | < 6 | 6 – 20 | > 20 |
| Goitre (WHO) | Stage 0-I | - | Stage II (Large) |
| Score | Class | Remission Probability |
|---|---|---|
| 0 – 1 | Class I | 70% |
| 2 – 3 | Class II | 44% |
| 4 – 6 | Class III | 16% |
Vos XG et al. • Eur J Endocrinol. 2016;The external validation study confirming the utility of the GREAT score in clinical practice.
Last Comprehensive Review: 2026
Scanning Medical Journals
No new significant updates or guidelines matching this topic were found today. We will check again soon.
